Newron reports positive mid-stage pain data
Italy's Newron Pharmaceuticals is reporting that its pain-killer ralfinamide significantly reduced neuropathic pain in a mid-stage trial. In addition, researchers said that the drug was well tolerated with side affects that were commensurate with a placebo. Analysts dubbed the news as an encouraging sign that the therapy merited further development, sending Newron's shares up in early trading. A Phase IIb trial is scheduled to get underway later this year. Analysts are now shifting their focus to safinamide, Newron's lead candidate for Parkinson's, which is due to deliver late-stage results.
- here's the AFX report
Related Articles:
FDA OKs Newron trials. Report
Italy's Newron gains $99 million in IPO. Report
Newron launches a Phase III trial on eve of IPO. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
